Sanofi Wins Aventis With $8 Bil. In Cash And Nominal Joint Control
Executive Summary
Sanofi's winning bid for Aventis includes an additional $8 bil. in cash, nominal joint control of the merged company, and an acknowledgment of Aventis' Franco-German heritage
You may also be interested in...
Sanofi-Aventis’ CEO Pipeline: R&D Chief Le Fur Tapped To Succeed Dehecq
Incoming Sanofi-Aventis CEO Gerard Le Fur will bring considerable research and development experience to the helm of the French drug maker
Sanofi-Aventis’ CEO Pipeline: R&D Chief Le Fur Tapped To Succeed Dehecq
Incoming Sanofi-Aventis CEO Gerard Le Fur will bring considerable research and development experience to the helm of the French drug maker
Sanofi-Aventis Picks Two U.S. Heads: Rothwell, Soriot On Management Cmte.
Sanofi-Aventis' U.S. business will be overseen by Sanofi U.S. CEO Tim Rothwell and Aventis U.S. Pharmaceutical Operations Head Pascal Soriot under a draft structure of the company's management team